Literature DB >> 8645039

Liver transplantation in infants younger than 1 year of age.

P M Colombani1, F G Cigarroa, K Schwarz, B Wise, W E Maley, A S Klein.   

Abstract

OBJECTIVE: The authors report on experience with liver transplantation for infants younger than 1 year of age. SUMMARY BACKGROUND DATA: Over the last 15 years, orthotopic liver transplant has become the only lifesaving procedure available for infants with end-stage liver disease. Many transplant centers initially required infants to reach a specific weight or age to minimize morbidity and mortality. Size-appropriate infant donors also were uncommon. As a result, many children, in the first few years of life, died of their disease. The availability of reduced-size cadaveric and living-related liver transplants has offered the ability to transplant the young infant with liver failure.
METHODS: The authors instituted a program to aggressively transplant infants with liver failure in the first year of life using both cadaveric and living-related liver donors.
RESULTS: Between June 1991 and January 1995, 13 infants were transplanted for rapidly progressive liver failure. Infant age ranged from 4 to 11 months (mean, 7.5 months). The cause of liver failure included biliary atresia (11), alpha 1-antitrypsin deficiency (1), and liver failure secondary to echovirus 7 (1). The United Network for Organ Sharing status at the time of transplant ranged from status 4, intensive care unit bound (4 patients); status 3, hospitalized (4 patients); or status 2, failing at home (5 patients). Six patients (46%) received cadaveric whole organ (2) or segmental transplants (4). Seven patients (54%) received left lateral segment living-related transplants from parental donors. After operation, patients received cyclosporine or FK506-based immunosuppression. Three patients (23%) required four retransplants (two cadaveric for primary nonfunction; one living-related for graft thrombosis in the face of fungal infection and bile leak). Postoperative complications included primary nonfunction (15%), rejection (85%), graft vascular thrombosis (15%, two of three revascularized successfully), bacterial and fungal infections (77%), and viral infections (46%). Epstein-Barr virus-associated lymphoproliferative developed in two patients (15%). Intestinal perforation requiring reoperation developed in two patients (15%). Bile leaks requiring reoperation or transhepatic stinting or both developed in three patients (23%). Two patients died in the perioperative period (< 1 month) from a combination of primary nonfunction or graft thrombosis and sepsis. Overall survival was 85%, ranging from 11.0 months to 4.5 years.
CONCLUSIONS: Orthotopic liver transplantation in infants younger than 1 year of age poses significant challenges from technical and infectious complications. Despite these barriers, overall patient survival is comparable to that of older children and adults.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8645039      PMCID: PMC1235207          DOI: 10.1097/00000658-199606000-00004

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  8 in total

1.  Application of reduced-size liver transplants as split grafts, auxiliary orthotopic grafts, and living related segmental transplants.

Authors:  C E Broelsch; J C Emond; P F Whitington; J R Thistlethwaite; A L Baker; J L Lichtor
Journal:  Ann Surg       Date:  1990-09       Impact factor: 12.969

2.  Reduced-size orthotopic liver transplantation: use in the management of children with chronic liver disease.

Authors:  J C Emond; P F Whitington; J R Thistlethwaite; E M Alonso; C E Broelsch
Journal:  Hepatology       Date:  1989-11       Impact factor: 17.425

3.  Reduction of morbidity and mortality from biliary complications after liver transplantation.

Authors:  A S Klein; S Savader; J F Burdick; J Fair; M Mitchell; P Colombani; B Perler; F Osterman; G M Williams
Journal:  Hepatology       Date:  1991-11       Impact factor: 17.425

4.  Pediatric liver transplantation.

Authors:  T E Starzl; C Esquivel; R Gordon; S Todo
Journal:  Transplant Proc       Date:  1987-08       Impact factor: 1.066

5.  Reduced-sized orthotopic liver graft in hepatic transplantation in children.

Authors:  H Bismuth; D Houssin
Journal:  Surgery       Date:  1984-03       Impact factor: 3.982

6.  Liver transplantation in children.

Authors:  R W Busuttil; P Seu; J M Millis; K M Olthoff; J R Hiatt; A Milewicz; B Nuesse; G el-Khoury; D Raybould; A Nyerges
Journal:  Ann Surg       Date:  1991-01       Impact factor: 12.969

7.  An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation.

Authors:  K L Cox; L S Lawrence-Miyasaki; R Garcia-Kennedy; E T Lennette; O M Martinez; S M Krams; W E Berquist; S K So; C O Esquivel
Journal:  Transplantation       Date:  1995-02-27       Impact factor: 4.939

8.  Pediatric liver transplantation: a 3-year experience.

Authors:  W S Andrews; E Wanek; B Fyock; S Gray; M Benser
Journal:  J Pediatr Surg       Date:  1989-01       Impact factor: 2.545

  8 in total
  3 in total

1.  Identification of neonatal liver failure and perinatal hemochromatosis in Canada.

Authors:  R Jackson; E A Roberts
Journal:  Paediatr Child Health       Date:  2001-05       Impact factor: 2.253

2.  Predictors of survival following liver transplantation in infants: a single-center analysis of more than 200 cases.

Authors:  Robert S Venick; Douglas G Farmer; Sue V McDiarmid; John P Duffy; Sherilyn A Gordon; Hasan Yersiz; Johnny C Hong; Jorge H Vargas; Marvin E Ament; Ronald W Busuttil
Journal:  Transplantation       Date:  2010-03-15       Impact factor: 4.939

3.  Long term outcomes of pediatric liver transplantation according to age.

Authors:  Jeik Byun; Nam-Joon Yi; Jeong-Moo Lee; Suk-won Suh; Tae Yoo; YoungRok Choi; Jae-Sung Ko; Jeong-Kee Seo; Hyeyoung Kim; Hae Won Lee; Hyun-Young Kim; Kwang-Woong Lee; Sung-Eun Jung; Seong-Cheol Lee; Kwi-Won Park; Kyung-Suk Suh
Journal:  J Korean Med Sci       Date:  2014-02-27       Impact factor: 2.153

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.